<![CDATA[Who Are The Key Candidates to Receive Subcutaneous Amivantamab for HNSCC?]]>

Summary

Dr. Barbara Burtness discussed eligibility criteria for amivantamab subcutaneous administration in head and neck squamous cell carcinoma patients within the OrigAMI-4 trial context, providing guidance on patient selection for tumor boards.